



CSL Limited
ABN: 99 051 588 348
655 Elizabeth Street
Melbourne
Victoria 3000 Australia
T +613 9389 1911
F +613 9389 1434
[CSL.com](https://www.csl.com)

ASX Announcement

For immediate release

14 June 2023

Market Update

CSL Limited (ASX:CSL; USOTC:CSLLY) today updates investors on the impact of foreign currency movements on the Company's fiscal year (FY) 23 forecast profit. CSL now expects a foreign currency headwind of ~USD \$230 million to \$250 million, up from USD \$175 million anticipated at the time of the half year result.

Constant currency profit guidance for FY23¹ remains unchanged, albeit now skewed to the top end of the range.

CSL also notes the broad range of published analyst profit projections for FY24. Following finalisation of next year's budget, CSL advises NPATA² is expected to grow ~13 – 18%³ to ~USD \$2.9 billion - \$3.0 billion at constant currency⁴.

In compiling financial forecasts, a number of key variables that may have a significant impact on guidance have been identified and are included in the footnote⁵.

Investor Call

CSL's Chief Executive Officer and Managing Director, Paul McKenzie and Chief Financial Officer, Joy Linton will today host a call to provide commentary on today's market update.

Date: Wednesday 14 June 2023

Time: 10.00am (AEST)

Please register via the following link: <https://sl.c-conf.com/diamondpass/10031358-jan4im.html>

Detailed financial and operational performance will be provided at the Company's results announcement on 15 August 2023.

Authorised by

Fiona Mead
Company Secretary

For further information, please contact:

Investors:

Bernard Ronchi
Director, Investor Relations
CSL Limited
P: +61 3 9389 3470
E: bernard.ronchi@csl.com.au

Stephen McKeon
Director, Investor Relations
CSL Limited
P: +61 402 231 696
E: stephen.mckeon@csl.com.au

Media:

Jimmy Baker
Communications
CSL Limited
P: +61 450 909 211
E: jimmy.baker@csl.com.au



For personal use only

¹ At CSL's result announcement in February 2023, the Company provided guidance for FY23 of:

- Revenue growth of 28 – 30% at constant currency¹, and
- NPATA¹ attributable to CSL shareholders of approximately \$2.7 billion to \$2.8 billion at constant currency.

² NPATA is adjusted to exclude impairment and amortisation of acquired intellectual property, business acquisition and integration costs and other acquisition accounting adjustments.

³ Growth calculations – estimates only:

	FY23 (USD)	Growth		FY24 (USD)		
Top end of NPATA guidance @ CC	\$2,800m					
FX Headwind – top end of estimate	~250m					
NPATA¹ guidance at reported rates	\$2,550m	13%	18%	\$2,880m	\$3,010m	@FY23 FX rates

⁴ Constant currency (CC) removes the impact of exchange rate movements, facilitating the comparability of operational performance.

⁵ Key variables that could cause actual results to differ materially include: the success and timing of research and development activities; decisions by regulatory authorities regarding approval of our products as well as their decisions regarding label claims; competitive developments affecting our products; the ability to successfully market new and existing products; difficulties or delays in manufacturing; ability to collect plasma; trade buying patterns and fluctuations in interest and currency exchange rates; legislation or regulations that affect product production, distribution, pricing, reimbursement, access or tax; acquisitions and divestitures; research collaborations; litigation or government investigations; and CSL's ability to protect its patents and other intellectual property.